This article is more than 5 years old. Information may no longer be current.
NIH to fund new grants for HIV research
Click Here to Manage Email Alerts
The National Institute of Allergy and Infectious Diseases of the NIH announced it will fund 5-year grants to three HIV research teams for a total of $14 million within the first year.
The grants are part of the Martin Delaney Collaboratory, designed to create public-private partnerships in HIV care, according to an NIH press release. “Martin Delaney was a true hero in the fight against HIV/AIDS, and he believed, as we do, that progress toward a cure for HIV/AIDS can be made through partnerships among scientists in government, industry and academia,” Anthony S. Fauci, MD, NIAID director, said in the release.
“These new grants, and the collaboratory to which they belong, are one way in which we honor his memory and advance his vision,” Fauci said.
The following research teams will receive the grants:
- Fred Hutchinson Cancer Research Center in Seattle, working with Sangamo BioSciences Inc., a biopharmaceutical company based in Richmond, Calif.;
- University of North Carolina at Chapel Hill, working with Merck Research Laboratories, based in Whitehouse Station, N.J.;
- University of California, San Francisco, and the Vaccine & Gene Therapy Institute of Florida in Port St. Lucie, Fla., working with Merck Research Laboratories.
“Each team will pursue a unique and complementary approach aimed at eradicating these remaining HIV reservoirs. To fulfill their role as members of a collaboratory, the teams will also meet periodically as their research progresses to find ways to work together,” NIH officials wrote in the release.
 |
Follow InfectiousDiseaseNews.com on Twitter. |